Robert Elgin, DO
Urology · Saint Clair Shores, MINPI 1053674101
Payments from drug & device makers
Across 201 payments — averaging $80.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Teleflex LLC$1K
- Ferring Pharmaceuticals Inc.$701
- Coloplast$463
- Myriad Genetic Laboratories, Inc.$385
- Boston Scientific$347
- plus $4K from 32 others
What the payments were for
- Consulting fees$8,22551%
- Travel & lodging$1,2828%
- Food & beverage$6,62941%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 8 | $9,139 |
| Teleflex LLC | 8 | $1,150 |
| Ferring Pharmaceuticals Inc. | 9 | $701 |
| Coloplast | 13 | $463 |
| Myriad Genetic Laboratories, Inc. | 13 | $385 |
| Boston Scientific | 8 | $347 |
| AbbVie(2 entities) | 21 | $341 |
| Antares Pharma, Inc. | 17 | $298 |
| Sumitomo Pharma America, Inc. | 14 | $297 |
| Axonics, Inc. | 4 | $250 |
| Calyxo, Inc. | 6 | $243 |
| Laborie Medical Technologies Corp. | 4 | $223 |
| Medtronic | 7 | $208 |
| Dornier Medtech America, Inc | 1 | $187 |
| Neotract Inc. | 4 | $178 |
| Procept Biorobotics Corporation | 2 | $172 |
| Biotissue Holdings Inc. | 1 | $161 |
| Photocure Inc | 2 | $150 |
| Innovation Technologies Inc | 1 | $123 |
| Astellas Pharma US Inc | 7 | $120 |
| Tolmar, Inc. | 7 | $115 |
| Olympus America Inc. | 5 | $97 |
| Urogen Pharma, Inc. | 3 | $97 |
| Endo Pharmaceuticals Inc. | 5 | $80 |
| Lumenis, Inc | 2 | $78 |
| Blue Earth Diagnostics | 5 | $73 |
| Amgen | 4 | $73 |
| Janssen Scientific Affairs, LLC | 2 | $58 |
| Bayer | 3 | $58 |
| Endo USA, Inc. | 3 | $55 |
| Pfizer | 2 | $46 |
| 180 Medical, Inc. | 2 | $36 |
| Merck | 1 | $33 |
| Tolmar Pharmaceuticals, Inc. | 2 | $29 |
| Halozyme Inc | 2 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Bioprotect Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$8,907
- UroLift$1,231
- FIRMAGON$487
- Prolaris$230
- Bulkamid$211
- TITAN$202
- Dornier MedTech$187
- Cysview$134
- CVAC Aspiration System$131
- RYBREVANT$125
- CARVYKTI$125
- Irrisept$123
- AQUABEAM SYSTEM$119
- Axonics$111
- ADSTILADRIN$104
- Porges Coloplast$101
How this compares
$16,149 in reported general payments places this provider in the 80th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 70 | $61,391 |
| GemtesaVibegron | 21 | $23,490 |
| Tamsulosin Hcl | 871 | $17,015 |
| Trospium Chloride ErTrospium Chloride | 59 | $13,422 |
| Finasteride | 511 | $9,292 |
| Methenamine Hippurate | 88 | $8,310 |
| Potassium Citrate ErPotassium Citrate | 95 | $7,318 |
| Solifenacin Succinate | 198 | $6,794 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 34 | $4,941 |
| Tolterodine Tartrate ErTolterodine Tartrate | 49 | $4,414 |
| Testosterone | 28 | $3,177 |
| Testosterone Cypionate | 59 | $3,094 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 71 | $2,942 |
| Dutasteride | 58 | $2,546 |
| Trospium Chloride | 26 | $1,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $120 | $61,39170 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $297 | $23,49021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 urology providers in Michigan.
Other urology in Saint Clair Shores
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- Kenneth KernenTroy$3.4M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
- Khurshid GhaniAnn Arbor$550K
- Richard BennettRoyal Oak$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.